Osteocyte metabolism on post-menopausal bone loss and role of hormone replacement therapy

2013 ◽  
Author(s):  
Ana Maria Silva ◽  
Ana Carolina Moreira ◽  
Maria Sancha Santos ◽  
Anabela Albuquerque ◽  
Izilda Ferreira ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Bone Loss ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Post Menopausal

scholarly journals Phyto-oestrogens and bone health

2008 ◽  
Vol 67 (2) ◽  
pp. 184-195 ◽  
Author(s):  
Véronique Coxam
Keyword(s):  
Hormone Replacement Therapy ◽  
Bone Loss ◽  
Replacement Therapy ◽  
Bone Health ◽  
Hormone Replacement ◽  
Early Period ◽  
Long Duration ◽  
Menopausal Women ◽  
Post Menopause ◽  
Post Menopausal

As oestrogen deficiency is the main cause in the pathogenesis of osteoporosis hormone-replacement therapy remains the mainstay for prevention. However, prophylaxis by hormone-replacement therapy is limited. Phyto-oestrogens, which are weakly-oestrogenic compounds present in plants, deserve particular mention because emerging data support the suggestion that they may prevent bone loss associated with the menopause. In the past few years extensive research using animal models has provided convincing data to indicate a significant improvement in bone mass or other end points following feeding with soyabean. Moreover, observational studies relate the lower incidence of osteoporosis among women in the Eastern world to a diet rich in phyto-oestrogens. However, it is not valid to extrapolate to the Western situation. The varied clinical trials that have been published suggest that isoflavones reduce bone loss in women in the early period post menopause, but a definitive result requires more investigations of the effect of phyto-oestrogens on bone health that have substantial sample size and are of long duration. In addition, the clinical efficacy of soya foods in preventing osteopenia depends on their intestinal metabolism. Thus, phyto-oestrogens are a source for putative innovative dietary health intervention for post-menopausal women. However, more data are necessary, particularly in relation to their effect on the risk of fracture.

scholarly journals Hormone replacement therapy in prophylactics and treatment of postmenopausal osteoporosis

2004 ◽  
Vol 53 (4) ◽  
pp. 69-75
Author(s):  
I. E. Zazerskaya ◽  
L. V. Kuznetcova
Keyword(s):  
Hormone Replacement Therapy ◽  
Bone Loss ◽  
Replacement Therapy ◽  
Postmenopausal Osteoporosis ◽  
Hormone Replacement ◽  
Postmenopausal Bone Loss

The article reviews the recent data (from 01.01.2002- 30.07.2004) concerning the role of HRT in prevention of postmenopausal bone loss and fractures. All the articles, that are included from Medline and Pub Med have been checked up in Cochran Controlled Register. The role of HRT remains great in treatment osteopenia. The effectiveness of HRT and depends on the length of duration, doses of estrogens, age of the patient.

Cyclical clodronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapy

2009 ◽  
Vol 10 (5) ◽  
pp. 697-703 ◽  
Author(s):  
Paolo Filipponi ◽  
Mariano Pedetti ◽  
Leone Fedeli ◽  
Luisella Cini ◽  
Renato Palumbo ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Bone Loss ◽  
Comparative Study ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Postmenopausal Bone Loss

Abstract TP197: Risk of Stroke in Women with use of Testosterone-Containing Hormone Replacement Therapy

Stroke ◽  
2017 ◽  
Vol 48 (suppl_1) ◽  
Author(s):  
Haseeb A Rahman ◽  
Ahmed Malik ◽  
Aesha Rahman ◽  
Saqib Chaudhry ◽  
Malik M Adil ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Risk Factor ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Stroke Risk ◽  
Hormone Replacement ◽  
Future Studies ◽  
Baseline Visit ◽  
Using Data

Background: There has been debate in the role of exogenous testosterone as a risk factor for stroke. Hormone replacement therapy (HRT) is considered a risk factor for stroke. The risk of ischemic stroke may increase when using testosterone-containing HRT. Methods: Using data from the observational component of the Women’s Health Initiative (WHI) [WHI Observational Study (OS)], we analyzed the 93,676 women aged 50-79 years, who participated in the OS over a period of 12±1 years. We compared the outcome of stroke in participants with reported use of a combination of testosterone and estrogen, estrogen alone, progesterone alone, and a combination of estrogen and progesterone, as recorded at the baseline visit. A logistic regression analysis was run to determine the odds of developing stroke. Results: Of the 93, 676 participants, 1772 used a combination of testosterone and estrogen (Estratest) HRT, 11,282 used progesterone alone, 10,808 used a combination of estrogen and progesterone, and 31,673 used estrogen alone. A smaller proportion of participants who developed an outcome of stroke had used Estratest as compared to estrogen alone or a combination of estrogen and progesterone (1.9% vs. 96.3% p=0.62). In the logistic regression, participants who had used Estratest were 1.2 times as likely to develop stroke as users of other hormone replacement therapy (OR 1.2 95%CI (0.96-1.6)), while women who had used progesterone only were 0.87 times less likely to develop stroke than users of other hormone replacement therapy (OR 0.874 95%CI (0.77-0.99)). After adjusting for confounders, the risk of developing stroke increased in users of Estratest (OR 1.25 95%CI (0.96-1.6) p=0.04), and decreased in users of progesterone only (OR 0.873 95%CI (0.77-0.99) p=0.038). Conclusion: Use of testosterone-containing HRT slightly increased the risk of stroke in women when compared to progesterone alone HRT, although this was not found to be significant. Stroke risk with Estratest may be considered to be similar to estrogen only and combination of estrogen plus progesterone HRT. Future studies are required to investigate these correlations.

Does hormone replacement therapy in post-menopausal women have any effect upon nasal physiology?

2008 ◽  
Vol 122 (7) ◽  
pp. 707-710 ◽  
Author(s):  
D C Wild ◽  
C M Philpott ◽  
C R Wolstenholme ◽  
G E Murty
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Oral Contraceptive Pill ◽  
Life Questionnaire ◽  
Female Hormone ◽  
Menopausal Women ◽  
Nasal Physiology ◽  
Post Menopausal ◽  
Age Range

AbstractBackground:Previous studies have suggested that the female menstrual cycle, pregnancy and the oral contraceptive pill have an effect upon nasal physiology.Objectives:This study aimed to assess the effects upon nasal physiology of female hormone replacement therapy in post-menopausal women. This has not been previously studied.Methods:Twenty post-menopausal women (age range 36 to 70 years; mean age 57.0 years) underwent measurements of the nasal airway, including anterior rhinoscopy, peak nasal inspiratory flow rate, acoustic rhinometry, anterior rhinomanometry, mucociliary clearance time and rhinitis quality of life questionnaire. Measurements of nasal patency were recorded prior to commencing hormone replacement therapy and at a time point 77–195 days (mean 101.9 days) following commencement.Results:There was no statistical difference found for any of the variables, using the paired t-test (p > 0.05 for all).Conclusions:Female hormone replacement therapy has no discernable effect upon nasal physiology and should not be considered a cause of rhinitic symptoms.

Sign in / Sign up

Export Citation Format

Share Document